Cardio.Flux Service

Our Cardio.Flux Service provides cardiac safety assessment by monitoring spontaneous Ca2+ transients in hiPSC-derived cardiomyocytes with the capability for high throughput (HT). Acute drug effects on the electrophysiology of cardiomyocytes can be detected with the Cardio.Flux Service. The service expedites decision making at early stages of preclinical drug development.

This service is based on fluorescence-based assays that measure changes of intracellular calcium transient parameters. Since calcium is the interdependent regulator between cardiomyocyte electrophysiology and contraction, compounds affecting ion channels can also affect intracellular calcium transients. For this assay, the hiPSC-derived cardioymocytes are cultured in standard 96 or 384 well plates and loaded with a calcium sensitive dye. Compound effects are assessed 30 min after the application of single doses and are compared to baseline recording.

Are you interested in disease models or patient-specific cardiomyocytes for your cardiovascular drug discovery studies? Please contact us to discuss the possibilities.


Service specifications

Cell type

Human iPSC-derived cardiomyocytes

Service type

Calcium-flux functional analysis


96 or 384 well plate

Time point

30 minute compound exposure

Compound concentrations*

0.1, 1, 10 µM in medium + 0.1 % DMSO (in triplicates)

Positive controls

L-type Ca2+ channel blocker: Nitrendipine

hERG blocker: Dofetilide

Vehicle control

0.1 % DMSO


Peak frequency (beat rate), peak amplitude, peak width diameter and proarrhythmic events


3 weeks (for up to 9 compounds)


A study protocol will be sent to initiate the study. Results are presented in draft and final study report.

*Suggested concentrations, to be agreed with client